6533b852fe1ef96bd12ab8f5

RESEARCH PRODUCT

Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants

Daniel LavanchyW. O. BöcherBrian J. McmahonGuido FrançoisUlus Salih AkarcaDavid FitzsimonsWolfgang JilgSusan GoldsteinAndrew J. HallBernard DuvalJ. E. BanatvalaAlessandro ZanettiAndré MeheusPierre Van DammeSheng-nan Lu

subject

Hepatitis B vaccineSettore MED/42 - Igiene Generale e ApplicataImmunization Secondarymedicine.disease_causeTimeOrthohepadnavirusparasitic diseasesHumanshepatitis B vaccination long-term efficacy virus mutantsMedicineHepatitis B VaccinesHepatitis B AntibodiesHepatitis B virusGeneral VeterinaryGeneral Immunology and MicrobiologybiologyImmunization Programsbusiness.industryPublic Health Environmental and Occupational HealthHepatitis BHepatitis Bbiology.organism_classificationmedicine.diseaseVirologyVaccinationInfectious DiseasesHepadnaviridaeDNA ViralMutationMolecular MedicineViral diseasebusinessViral hepatitisImmunologic Memorygeographic locations

description

The long-term efficacy of hepatitis B vaccine, long-term effectiveness of hepatitis B immunisation programmes, immune memory induced by hepatitis B vaccine, current booster policies, and impact of hepatitis B virus mutants on immunisation programmes were reviewed at the Viral Hepatitis Prevention Board (VHPB) meeting in Sevilla, Spain, March 2004. The main focus was on universal vaccination programmes with data being presented from Italy, Saudi Arabia, Singapore, Spain, Taiwan, Thailand, The Gambia, and USA (Alaska).

yearjournalcountryeditionlanguage
2005-01-01Vaccine
https://doi.org/10.1016/j.vaccine.2005.03.017